Research graph
References from Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiple myeloma
10.1016/s0140-6736(21)00135-5 · 2021 · External reference
Novel agents as main drivers for continued improvement in survival in multiple myeloma
10.3390/cancers15051558 · 2023 · External reference
Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)
10.1016/j.annonc.2020.11.014 · 2021 · External reference
Lenalidomide, bortezomib, and bexamethasone with transplantation for myeloma
10.1056/nejmoa1611750 · 2017 · External reference
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
10.3324/haematol.2020.247130 · 2021 · External reference
Consolidation and maintenance in newly diagnosed multiple myeloma
10.1200/jco.21.01045 · 2021 · External reference
Triplet therapy, transplantation, and maintenance until progression in myeloma
10.1056/nejmoa2204925 · 2022 · External reference
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome
10.1056/nejm199607113350204 · 1996 · External reference
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
10.1056/nejmoa1606038 · 2016 · External reference
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa1607751 · 2016 · External reference
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
10.1056/nejmoa1714678 · 2018 · External reference
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
10.1056/nejmoa1817249 · 2019 · External reference
Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development
10.1177/2040620715572295 · 2015 · External reference
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
10.1186/s13045-016-0283-0 · 2016 · External reference
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
10.1182/blood.2020005288 · 2020 · External reference
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
10.1016/s0140-6736(19)31240-1 · 2019 · External reference
10.1016/s1470-2045(21)00428-9
10.1016/s1470-2045(21)00428-9 · 2021 · External reference
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa2312054 · 2024 · External reference
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible
10.1007/s00277-015-2537-2 · 2016 · External reference
Cyclophosphamide, thalidomide, and dexamethasone as initial therapy for patients with newly diagnosed multiple myeloma in a middle-income country: 7-year follow-up
10.1200/go.20.00665 · 2021 · External reference
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results
10.3324/haematol.2011.043372 · 2012 · External reference
Epidemiology of hematologic malignancies in real-world settings: findings from the hemato-oncology Latin America observational registry study
2019 · External reference
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
10.1016/s1470-2045(14)70442-5 · 2014 · External reference
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
10.1200/jco.2003.03.139 · 2003 · External reference
Median follow-up in clinical trials
10.1200/jco.1991.9.1.191 · 1991 · External reference
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma
10.1200/jco.21.01935 · 2022 · External reference
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
10.1038/s41408-023-00794-x · 2023 · External reference
Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk?
10.1200/jco.22.00504 · 2022 · External reference
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S
10.1053/j.seminoncol.2022.01.011 · 2022 · External reference
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality -cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)
10.1016/j.htct.2023.08.002 · 2024 · External reference
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
10.3324/haematol.2021.279459 · 2022 · External reference
